We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Committee Votes to Delay Myeloma Drug Approval
FDA Advisory Committee Votes to Delay Myeloma Drug Approval
The FDA’s Oncologic Drugs Advisory Committee voted 8 to 5 on Tuesday in favor of delaying the approval of Karyopharm Therapeutics’ NDA for selinexor, a multiple myeloma treatment, pending the results of a Phase 3 trial.